Singapore Oncology Drugs Market Size, Competitive Landscape, Regional Outlook and Driving Factors Analysis 2028

The Singapore Oncology Drugs Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Singapore Oncology Drugs market. This report explores all the key factors affecting the growth of the global Singapore Oncology Drugs market, including demand-supply scenario, pricing structure, profit margins, production, and value chain analysis.

Get PDF Sample Report Now! @ https://www.prudentmarkets.com/sample-request/141833/

Report Description of the Singapore Oncology Drugs Market

Research Scope and Assumption

The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)
The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis
We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses
All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis
Inflation has not been accounted for in order to estimate and forecast the market
Numbers may not add up due to rounding off

Research Objective:

To analyze and forecast the market size of Singapore Oncology Drugs Drugs market
To classify and forecast Singapore Oncology Drugs Market market based on application, drugs, project type, and application.
To identify drivers and challenges for Singapore Oncology Drugs market
To examine competitive developments such as mergers and acquisitions, agreements, collaborations and partnerships, etc., in Singapore Oncology Drugs market
To conduct pricing analysis for Singapore Oncology Drugs Drugs market
To identify and analyze the profile of leading players operating in Singapore Oncology Drugs market

Reason to buy the report:

Facilitate decision-making based on strong current and forecast data for Atopic Dermatitis drug market
Develop strategies based on the latest regulatory framework
Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market
Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Atopic Dermatitis market
Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders
To strategically profile key players and comprehensively analyze their market shares and core competencies
We have technically sound team which do a deep dive research and also provide strategy-based consulting analysis

Singapore Oncology Drugs Market Executive Summary

In Singapore cancer cases have been rising over the years, and the number of people living with cancer will continue to increase. During the period from 2014-2018, 74,536 cancer cases were reported in Singapore and 48.5% and 51.5% of those cases were reported in males and females respectively. Thus growing the incedence of cancer cases is likely to drive the growth of the Singapore oncology drugs market.

Market Size and Key Findings

The Singapore Oncology Drugs market size is at around USD xx billion in 2021 and is projected to reach USD xx billion in 2028, exhibiting a CAGR of xx% during the forecast period.

In 2019 cancer accounts for 28.4% of all deaths in Singapore. The number of cancer cases increased nearly 6 times from 12,072 in 1968-1972 to 71,265 in 2013-2017.This meant that an average of 14,253 cancer diagnoses are reported every year, equating to around 39 Singaporeans being diagnosed with cancer every single day.Consequently these factors likely to drive the growth of the Oncology market in Singapore during the forecast period.

Market Dynamics

Market Growth Drivers Analysis

Major factors driving the Singapore oncology drugs market are rising Prevalence of Cancer, growing government Initiatives for cancer awareness, increasing patient assistance programs (PAPs). Furthermore, increase in R&D and the rising prevalence of various types of cancer across the globe.

Market Restraints

High cost of cancer therapies and fluctuation in reimbursement policies are the factors affecting the Singapore oncology drugs market negatively.

Competitive Landscape

Key Players

Key market players in Singapore Oncology Drugs market include Abbvie, Amgen, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, Eli Lilly, Johnson & Johnson, Hoffmann-La Roche Ltd, Sanofi and Others

Products in Pipeline

May 19, 2021 The Janssen Pharmaceutical Companies of Johnson & Johnsonannounced new data from the fixed-duration cohort of the investigational Phase 2 CAPTIVATE study, showing that 95 percent of patients treated with combined IMBRUVICAplus venetoclax were alive and progression-free at two years. Deep remissions were seen across all subgroups, including patients with high-risk chronic lymphocytic leukemia (CLL).In addition, long-term data from the RESONATE-2 (PCYC-1115/1116) study will be presented, providing the longest follow-up Phase 3 data for any BTK inhibitor to date. These data reinforce the long-term survival benefits and well-established safety profile of single-agent IMBRUVICAfor patients with CLL.

Notable Recent Deals

July 27, 2021 -- Amgen (NASDAQ: AMGN) and Teneobio announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 billion in cash.

The acquisition will also add TNB-585, a Phase 1 bispecific T cell-engager for the treatment of metastatic castrate-resistant prostate cancer (mCRPC), and several preclinical oncology pipeline assets with the potential for near-term IND filings. TNB-585 complements Amgen's existing prostate cancer portfolio, which includes acapatamab (formerly AMG 160) and AMG 509, both in Phase 1. Each of these three investigational therapies uses a different approach to treat a highly prevalent disease for which new treatment options are very much needed.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario of Singapore Oncology Drugs Services

The Government has accepted the MediShield Life Councils recommendations to create a list of clinically proven and cost-effective outpatient cancer drug treatments, allow these cancer drug treatments to be claimable under MediShield Life, and set more granular claim limits to provide better coverage based on the cost of each treatment.

Subsidised patients in the public healthcare institutions currently receive up to 75% subsidy for drugs under the Standard Drug List (SDL) and MAF. Following price negotiations with drug manufacturers to achieve better drug prices and cost-effectiveness, 55 more cancer drugs will be listed under the SDL/MAF, which will increase support for around 150 cancer drug treatments. The new MediShield Life claim limits for cancer drug treatments will be set based on post-subsidy bills.

To Know More About COVID-19 Impact On Singapore Oncology Drugs Market @ https://www.prudentmarkets.com/sample-request/141833/

Oncology Drugs Market Segmentation

By Therapy Modality Type:

Availability of various advance oncology treatment such as targeted therapy and hormonal therapy among others will enhance the segment expansion.

Chemotherapy
Immunotherapy
Target Therapy
Hormonal Therapy
Other Therapy Type

By Cancer Type:

The cancer segment is expected to rise exponentially during the forecast period. The growing prevalence of cancer and rising awareness regarding therapeutics will boost the segment's growth.

Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Respiratory/Lung Cancer
Skin Cancers
Other Cancers

By End User Type:

Based on End User type the market is segmented into hospitals, speciality clinics and radiation therapy centers.

Hospitals
Speciality Clinics
Radiation Therapy Centers

Prudent Markets provides attractive discounts that fit your needs. Customization of the reports as per your requirement is also offered. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Speak To Our Analyst For A Discussion On The Above Findings, And Ask For A Discount On The Report @ https://www.prudentmarkets.com/discount-request/141833/

The report covers the competitive analysis of the market. As the demand is driven by a buyer's paying capacity and the rate of item development, the report shows the important regions that will direct growth. This section exclusively shares insight into the budget reports of big-league members of the market helping key players and new entrants understand the potential of investments in the Global Singapore Oncology Drugs Market. It can be better employed by both traditional and new players in the industry for complete know-how of the market.

Strategic Points Covered in Table of Content of Global Singapore Oncology Drugs Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Singapore Oncology Drugs market
Chapter 2: Exclusive Summary - the basic information of the Singapore Oncology Drugs Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Singapore Oncology Drugs
Chapter 4: Presenting the Singapore Oncology Drugs Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Singapore Oncology Drugs market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Any Questions? Feel Free To Enquire Here. We Will put you on the Right Path @ https://www.prudentmarkets.com/enquiry-request/141833/

Free Customization on the basis of client requirements on Immediate purchase:
1- Free country-level breakdown of any 5 countries of your interest.
2- Competitive breakdown of segment revenue by market players.

Customization of the Report:
This report can be customized to meet the client's requirements. Please connect with our sales team (sales@prudentmarkets.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +91 83560 50278 || USA/Canada(Toll Free): 1800-601-6071 to share your research requirements.

Get ready to Recognize the pros and cons of the regulatory framework, local reforms, and its effect on the Industry. Understand how the Leaders in Intelligent Network are keeping themselves one stage forward with our most up-to-date survey analysis.

In conclusion, the Singapore Oncology Drugs Market report is a genuine source for accessing the research data which is projected to exponentially grow your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis and PESTLE analysis is also incorporated in the report.

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.